Skip to main content
Journal ArticleOPEN ACCESS

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis

  • Kovacsovics-Bankowski M
  • Chisholm L
  • Vercellini J
  • et al.
Journal for ImmunoTherapy of Cancer (2013) 1(S1)
DOI: 10.1186/2051-1426-1-s1-p255
N/ACitations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Meeting abstracts OX40, a member of the Tumor Necrosis Factor Receptor superfamily is a potent co-stimulatory molecule. OX40 engagement increases T cell proliferation, effector function and survival. Pre-clinical studies have shown that OX40 agonist synergizes with radiation and cyclophosphamide to

Cite

CITATION STYLE

APA

Kovacsovics-Bankowski, M., Chisholm, L., Vercellini, J., Crittenden, M., Lary, S., Curti, B., & Weinberg, A. (2013). Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis. Journal for ImmunoTherapy of Cancer, 1(S1). https://doi.org/10.1186/2051-1426-1-s1-p255

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free